Key facts
- It has raised $3.0M; the latest was Seed Round ($3.0M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for VisiRose
- ·The full record, as it builds
Funding rounds
No funding rounds for VisiRose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VisiRose
Developer of a rose bengal photodynamic antimicrobial therapy designed to treat eye infections. The company offers a bioactive synthetic small molecule for treatments for Infectious Keratitis and other eye diseases, enabling healthcare professionals to address ocular infections with a targeted and non-invasive approach.
- Sector
- Healthcare
- HQ
- Knoxville, TN, United States
- Founded
- 2024
- Employees
- 3
- Website
- visirose.com/
- Ownership
- Privately Held (backing)
VisiRose doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VisiRose shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VisiRose in its N-PORT filings yet. We sweep new filings monthly.